Loading company…
Rongcan Biotech develops nucleic acid drugs, including mRNA and siRNA products.
Rongcan Biotech develops nucleic acid medicines, including mRNA and siRNA drugs for respiratory, cardiovascular and solid tumor conditions, as well as mRNA vaccines for infectious diseases. Founded in 2020, the company is based in Wuhu, China, and has research collaborations with Shanghai Jiao Tong University School of Pharmacy, WuXi AppTec Group and HuiGene Therapeutics. In December 2023, it raised more than CNY 100 million in Series A funding.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in